Technical Analysis for CMPS - COMPASS Pathways Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Historical CMPS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 7.55% | |
| 50 DMA Resistance | Bearish | 7.81% | |
| Bearish Engulfing | Bearish | 7.81% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 7.81% | |
| Wide Bands | Range Expansion | 7.81% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 6.60% | |
| Narrow Range Bar | Range Contraction | 6.60% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Trending on StockTwits | 1 day ago | |
| Up 1 ATR | 1 day ago | |
| Rose Above 20 DMA | 1 day ago | |
| 60 Minute Opening Range Breakout | 1 day ago | |
| Rose Above 50 DMA | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/12/2020
COMPASS Pathways Plc Description
COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.
Classification
Sector: Other
Industry: Other
Keywords: Health Sciences Drug Discovery Mental Health FDA Psychoactive Drugs Entheogens Major Depressive Disorder Depression Breakthrough Therapy MP3 Treatment Resistant Depression
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 61.69 |
| 52 Week Low | 22.53 |
| Average Volume | 337,094 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 46.57 |
| 20-Day Moving Average | 46.85 |
| 10-Day Moving Average | 44.22 |
| Average True Range | 3.99 |
| ADX | 19.08 |
| +DI | 24.91 |
| -DI | 19.13 |
| Chandelier Exit (Long, 3 ATRs ) | 48.90 |
| Chandelier Exit (Short, 3 ATRs ) | 51.06 |
| Upper Bollinger Band | 55.69 |
| Lower Bollinger Band | 38.02 |
| Percent B (%b) | 0.58 |
| BandWidth | 37.73 |
| MACD Line | -1.07 |
| MACD Signal Line | -1.06 |
| MACD Histogram | -0.0089 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 55.40 | ||||
| Resistance 3 (R3) | 54.88 | 52.00 | 54.22 | ||
| Resistance 2 (R2) | 52.00 | 50.20 | 52.26 | 53.83 | |
| Resistance 1 (R1) | 50.16 | 49.08 | 51.08 | 50.68 | 53.43 |
| Pivot Point | 47.28 | 47.28 | 47.74 | 47.54 | 47.28 |
| Support 1 (S1) | 45.44 | 45.48 | 46.36 | 45.96 | 43.21 |
| Support 2 (S2) | 42.56 | 44.36 | 42.82 | 42.81 | |
| Support 3 (S3) | 40.72 | 42.56 | 42.42 | ||
| Support 4 (S4) | 41.24 |
